J Nacho 11
Tue, Jan-24-06, 16:17
CLINICAL RESULTS: Joe Vinson, Ph.D. at the University of
Scranton(HEART HEALHT)
j_nacho_11@axtel.net
In a recent clinical trial conducted by Dr. Joe Vinson at the
University of Scranton, Rel=ECv CardioSentials significantly
decreased total cholesterol, LDL (bad) cholesterol and
triglycerides in a sub-set of test subjects with high
cholesterol. In addition, Rel=ECv CardioSentials increased HDL
(good) cholesterol and reduced blood glucose levels.
for all the information: http://www.reliv.com/docs/nutritiona-
ls/CardioSentialsBrochure.pdf
Rel=ECv CardioSentials Takes Aim Rel=ECv recognizes that
simply lowering cholesterol isn't enough. Total heart health
The Rel=ECv Clinical Trial:
******************************RESULTS************************-
**************=
*****************
Joe Vinson, Ph.D. and Professor of Chemistry at the
University of Scranton, conducted a 16-week randomized
double-blind, placebo-controlled crossover study (the "gold
standard" in clinical trials) to determine the safety and
effectiveness of Rel=ECv CardioSentials in reducing key risk
factors for cardiovascular disease.
The study tested two groups - individuals taking statin
medications and individuals who were not on statins. Both
groups experienced significant antioxidant benefits from
Rel=ECv CardioSentials that supports heart health by defending
against lipid oxidation. In addition:
Non-Statin Group - Taken once daily, Rel=ECv CardioSentials
significantly reduced total cholesterol, LDL (bad) cholesterol
and glucose, and raised HDL (good) cholesterol and lowered
triglycerides. It significantly decreased the overall risk
factor for heart disease.
Statin Group - Rel=ECv CardioSentials caused no adverse
interaction with statin medication, and members of the group
saw improvements in their average risk factor due to a
significant decrease in LDL (bad cholesterol). These subjects
also experienced a glucose decrease.
Risk Reduction - According to the clinical results, Rel=ECv's
total heart health formula was also shown to reduce the
10-year risk for developing cardiovscular disease, based on
the risk assessment tool developed by the "National
cholesterol education program"
recent clinical trial conducted by Dr. Joe Vinson at the
University of Scranton, Rel=ECv CardioSentials significantly
decreased total cholesterol, LDL (bad) cholesterol and
triglycerides in a sub-set of test subjects with high
cholesterol. In addition, Rel=ECv CardioSentials increased
HDL (good) cholesterol and reduced blood glucose levels.
also shown to reduce the 10-year risk for developing
cardiovascular disease, on the Risk Assessment tool developed
by the "National Cholesterol Education Program." The effects
of the product on heart disease were all beneficial to the
subjects. These include lipids, lipid oxidation and glucose.
In other words, the product improves total heart health in
people who have high cholesterol, even those taking statins.
Dr. Joe Vinson Professor of Chemistry, University of Scranton
FOR MORE INFORMATION : OR TO ORDER send me an e-mail:
j_nacho_11@axtel.net
Scranton(HEART HEALHT)
j_nacho_11@axtel.net
In a recent clinical trial conducted by Dr. Joe Vinson at the
University of Scranton, Rel=ECv CardioSentials significantly
decreased total cholesterol, LDL (bad) cholesterol and
triglycerides in a sub-set of test subjects with high
cholesterol. In addition, Rel=ECv CardioSentials increased HDL
(good) cholesterol and reduced blood glucose levels.
for all the information: http://www.reliv.com/docs/nutritiona-
ls/CardioSentialsBrochure.pdf
Rel=ECv CardioSentials Takes Aim Rel=ECv recognizes that
simply lowering cholesterol isn't enough. Total heart health
The Rel=ECv Clinical Trial:
******************************RESULTS************************-
**************=
*****************
Joe Vinson, Ph.D. and Professor of Chemistry at the
University of Scranton, conducted a 16-week randomized
double-blind, placebo-controlled crossover study (the "gold
standard" in clinical trials) to determine the safety and
effectiveness of Rel=ECv CardioSentials in reducing key risk
factors for cardiovascular disease.
The study tested two groups - individuals taking statin
medications and individuals who were not on statins. Both
groups experienced significant antioxidant benefits from
Rel=ECv CardioSentials that supports heart health by defending
against lipid oxidation. In addition:
Non-Statin Group - Taken once daily, Rel=ECv CardioSentials
significantly reduced total cholesterol, LDL (bad) cholesterol
and glucose, and raised HDL (good) cholesterol and lowered
triglycerides. It significantly decreased the overall risk
factor for heart disease.
Statin Group - Rel=ECv CardioSentials caused no adverse
interaction with statin medication, and members of the group
saw improvements in their average risk factor due to a
significant decrease in LDL (bad cholesterol). These subjects
also experienced a glucose decrease.
Risk Reduction - According to the clinical results, Rel=ECv's
total heart health formula was also shown to reduce the
10-year risk for developing cardiovscular disease, based on
the risk assessment tool developed by the "National
cholesterol education program"
recent clinical trial conducted by Dr. Joe Vinson at the
University of Scranton, Rel=ECv CardioSentials significantly
decreased total cholesterol, LDL (bad) cholesterol and
triglycerides in a sub-set of test subjects with high
cholesterol. In addition, Rel=ECv CardioSentials increased
HDL (good) cholesterol and reduced blood glucose levels.
also shown to reduce the 10-year risk for developing
cardiovascular disease, on the Risk Assessment tool developed
by the "National Cholesterol Education Program." The effects
of the product on heart disease were all beneficial to the
subjects. These include lipids, lipid oxidation and glucose.
In other words, the product improves total heart health in
people who have high cholesterol, even those taking statins.
Dr. Joe Vinson Professor of Chemistry, University of Scranton
FOR MORE INFORMATION : OR TO ORDER send me an e-mail:
j_nacho_11@axtel.net